









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on 3rd August 2022

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
2) New Requests				
Saciztuzumab govitecan	RED			Free of charge scheme (will be NHSE commissioned). HUTH only.
3) New formulations & extensions to use				
Sterile talcum powder	RED			For Pleurodesis – NLAG application for inpatient use only. Already on HUTH formulary; addition to NLAG formulary

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Mydraine® Tropicamide, phenylephrine and lidocaine intracameral injection	RED			For dilation of pupils and local anaesthetic at start of cataract surgery – NLAG. Already on HUTH formulary; addition to NLAG formulary
4) Products considered by NICE				
Berotralostat (TA738)	RED			NHSE homecare via HUTH only (immunology)
Mogamulizumab (TA754)	RED			NHSE HUTH only
Tucatinib (TA786)	RED			NHSE HUTH and NLAG
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary and formulary chapter decisions by the APC				
None – chapter 2 deferred due to time				

The following guidelines were presented to and approved at the August 2022 meeting of the APC:

- LVSD medicines management pathway -
- Type 2 diabetes (Hull and ERY)
- Guideline for overactive bladder In Females (NL/NEL only currently)

The following Green/Amber 1/Amber 2 drug information leaflets were presented to and approved at the August 2022 meeting of the APC:

- Buprenorphine leaflet Hull and East Riding only
- PPI information

The following shared care guidelines were presented to and approved at the August 2022 meeting of the APC:

- None

Other documents presented to and approved at the August 2022 meeting of the APC:

- Palliative care Hull and East Riding only